Therapy resistance on the RADar in ovarian cancer

Ovarian cancer has the worst prognosis of all gynecological cancers with high‐grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwickert, Jonas, Zickgraf, Franziska M, Sprick, Martin R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103092/
https://www.ncbi.nlm.nih.gov/pubmed/33779077
http://dx.doi.org/10.15252/emmm.202114010
Descripción
Sumario:Ovarian cancer has the worst prognosis of all gynecological cancers with high‐grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high‐grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021).

Ejemplares similares